Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24;12(7):2489.
doi: 10.3390/jcm12072489.

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions

Affiliations

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions

Francesca Girolami et al. J Clin Med. .

Abstract

Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

Keywords: cascade testing; genetic counselling; genetic testing; hypertrophic cardiomyopathy; multidisciplinary team; next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Genetic testing strategy in HCM. Abbreviations: HCM: hypertrophic cardiomyopathy; VUS: variant of uncertain significance.

References

    1. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur. Heart J. 2014;35:2733–2779. - PubMed
    1. Maron B.J., Desai M.Y., Nishimura R.A., Spirito P., Rakowski H., Towbin J.A., Dearani J.A., Rowin E.J., Maron M.S., Sherrid M.V. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2022;79:390–414. doi: 10.1016/j.jacc.2021.11.021. - DOI - PubMed
    1. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet. 2013;381:242–255. doi: 10.1016/S0140-6736(12)60397-3. - DOI - PubMed
    1. Braunwald E., Lambrew C.T., Rockoff S.D., Ross J., Jr., Morrow A.G. Idiopathic Hypertrophic Subaortic Stenosis. I. A Description of the Disease Based Upon an Analysis of 64 Patients. Circulation. 1964;30((Suppl. S4)):3–119. doi: 10.1161/01.CIR.29.5S4.IV-3. - DOI - PubMed
    1. Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., Evanovich L.L., Hung J., Joglar J.A., Kantor P., et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2020;76:3022–3055. doi: 10.1016/j.jacc.2020.08.044. - DOI - PubMed

LinkOut - more resources